Reuters logo
BRIEF-Ose Immunotherapeutics presents new data on Selective Anti-SIRPa OSE-172 (Effi-DEM)
May 15, 2017 / 5:48 PM / 5 months ago

BRIEF-Ose Immunotherapeutics presents new data on Selective Anti-SIRPa OSE-172 (Effi-DEM)

May 15 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* WHEN USED AS MONOTHERAPY OR COMBINED WITH ACTIVATORS OF T-CELL RESPONSE, ANTI-PD-L1 AND ANTI-41BB, OSE-172 WAS VERY EFFECTIVE

* USED AS MONOTHERAPY OR COMBINED WITH ACTIVATORS OF T-CELL RESPONSE OSE-172 ALLOWED EFFECTOR MACROPHAGES AND T-CELLS TO WORK TOGETHER WITH SIGNIFICANT TUMOR SHRINKAGE

* IN PARALLEL WITH TRANSFORMATION OF SUPPRESSIVE INTO EFFECTOR MYELOID CELLS, TUMOR MICRO-ENVIRONMENT WAS ALSO DRAMATICALLY MODIFIED

* TUMOR MICRO-ENVIRONMENT DRAMATICALLY MODIFIED: ALLOWING INTRA-TUMORAL ACCUMULATION OF CYTOLYTIC NATURAL KILLER (NK) AND OF EFFECTOR B CELLS

* “OUR MYELOID CHECKPOINT INHIBITOR OSE -172 DEMONSTRATES STRONG IMPACT ON TUMOR MICRO-ENVIRONMENT BEYOND MYELOID CELLS” - CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below